<- Hard dé e: 0.033332109451294 sec -> By obtaining the exclusive worldwide license to inhale insulin MannKind Corporation, the pharmaceutical group Sanofi completes its offer in the field of treatment against diabetes, which he is a key component of its growth.
The agreement signed with Sanofi American biotechnology company for its powdered insulin will reach a total of 925 million dollars (690 million euros), said Monday two companies.
This product, called Afrezza, which “is a new insulin inhaler fast action for the treatment of diabetes types 1 and 2 in adults, “to be launched in the United States in the first quarter 2015, said the joint statement.
MannKind Corporation will receive an initial payment of $ 150 million and subsequently milestone payments that could reach 775 million (an aggregate of $ 925 million or less) if “specific targets in terms of development, regulatory and sales thresholds” are met.
States in the development and marketing of Afrezza, MannKind Sanofi and will share all losses and profits to the tune of 65% and 35%.
The drugmaker also agreed to make an advance of MannKind’s share of spending up to a maximum of $ 175 million.
The collaboration agreement provides that Sanofi will be responsible for development, regulatory processes and commercialization of the product. Under a separate agreement, MannKind Afrezza will manufacture at its plant in Danbury, Connecticut (north-eastern United States).
“The two companies also plan to work together to increase production capacity if it was needed to meet global demand, “the statement said.
” Afrezza adds to our portfolio of solutions for diabetes that is expanding, “said Pierre Chancel, Senior Vice-President responsible for
diabetes division of Sanofi, said in the statement. “She is uniquely positioned to provide patients a new treatment option based on insulin to manage their diabetes without the need for multiple daily injections” Has he explained
-. sprays, patches, pills –
The agreement “allows the company, leader in the management of diabetes, to provide another option based on insulin for diabetics around the world “patients, assures the group.
new treatments against diabetes is one of seven growth platforms identified by the CEO of Sanofi, Chris Viehbacher.
incidence of diabetes is increasing in developed countries, experts have sometimes been able to evoke an epidemic, including agribusiness origin is singled out.
United States in 2012 and counted more than 29 million diabetes, according to federal Centers for Disease Control and Prevention (CDC).
type 1 diabetes, the most severe form of the disease most commonly affects children, whereas type 2 diabetes, which represents nearly 90% of cases, most often occurs in adults, usually overweight.
In both cases, the dysfunction of the pancreas can not produce enough insulin, the hormone to maintain levels normal blood glucose, makes it compulsory treatment at regular intervals.
Faced with these constraints, the big pharmaceutical companies have been working for several years on alternative modes of administration for injection intravenously or subcutaneously and insulin pumps.
pills, sprays, patches, syringes without pain, the tracks are varied and in this context, Sanofi revealed in June that it has entered a “strategic alliance” with the American Medtronic, expert in miniaturization and implantable devices.
Posing as a whistle, Afrezza requires use before meals. Among the set associated with this medicine that child care is not to be used for patients with chronic respiratory disease such as asthma.
American Pfizer was terminated in October 2007 to the commercialization of the Exubera inhaled insulin, revealing later to have been an increase in cases of lung cancer among former patients smoking.
Sanofi also announced in June that its new insulin formulation called Toujeo intended to replace the insulin Current Lantus, produced “positive” results in clinical phase III trials, the last step before commercialization.
No comments:
Post a Comment